Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University
Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases
Related news for (HSTO)
- Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Adjournment of Special Meeting of Stockholders
- Histogen Announces Board Approval of Complete Liquidation and Dissolution